Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population
- 15 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Dermatological Treatment
- Vol. 33 (3), 1638-1642
- https://doi.org/10.1080/09546634.2021.1886231
Abstract
This is an Italian single-center retrospective study evaluating safety and efficacy of biologic agents in psoriatic patients with a previous diagnosis of malignant cancer. Management of moderate and severe psoriasis patients with a past medical history of malignancies could be difficult because biologic agents are historically associated with a presumptive increased risk of neoplastic reactivation or of a new incoming cancer. The aim of this study is to assess the safety of biologics in patients with a previous cancer diagnosis. The study analyzed 16 moderate to severe psoriasis patients with a diagnosis of malignant cancer in the previous 10 years treated with biologic agents for up to at least 96 weeks. In five of these patients, cancer was diagnosed in the previous 5 years. We observed a rapid decrease in PASI (psoriasis area severity index) reaching a 90% improvement in 100% of patients. Oncologic follow up did not show any worsening or reactivation of cancer during the entire observation period. No new malignancies were observed in the analyzed sample. Biologic agents in our experience have demonstrated to be safe and effective in psoriatic patients with a past medical history of malignant cancer.Keywords
This publication has 36 references indexed in Scilit:
- Interleukin 17A Promotes Gastric Cancer Invasiveness via NF-κB Mediated Matrix Metalloproteinases 2 and 9 ExpressionPLOS ONE, 2014
- Psoriasis as a systemic diseaseClinics in Dermatology, 2014
- Risk of cancer in psoriasis: a systematic review and meta‐analysis of epidemiological studiesJournal of the European Academy of Dermatology and Venereology, 2013
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upBritish Journal of Dermatology, 2013
- Interleukin-17 Promotes Formation and Growth of Prostate Adenocarcinoma in Mouse ModelsCancer Research, 2012
- The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trialsJournal of the American Academy of Dermatology, 2011
- Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversiesClinics in Dermatology, 2010
- Malignancy After Solid Organ Transplantation: An OverviewThe Oncologist, 2008
- Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptideNature, 2007
- PUVA and cancer risk: the Swedish follow-up studyBritish Journal of Dermatology, 1999